Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Add as a preferred source on Google
Heidelberg, Germany, February 28, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. (ET) in Boston.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
